148 related articles for article (PubMed ID: 33477712)
1. Oxidised LDL and Anti-Oxidised LDL Antibodies Are Reduced by Lipoprotein Apheresis in a Randomised Controlled Trial on Patients with Refractory Angina and Elevated Lipoprotein(a).
Khan TZ; Hartley A; Haskard D; Caga-Anan M; Pennell DJ; Collins P; Barbir M; Khamis R
Antioxidants (Basel); 2021 Jan; 10(1):. PubMed ID: 33477712
[No Abstract] [Full Text] [Related]
2. The impact of lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a): Objectives and methods of a randomised controlled trial.
Khan TZ; Pottle A; Pennell DJ; Barbir MS
Atheroscler Suppl; 2015 May; 18():103-8. PubMed ID: 25936312
[TBL] [Abstract][Full Text] [Related]
3. Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial.
Khan TZ; Gorog DA; Arachchillage DJ; Ahnström J; Rhodes S; Donovan J; Banya W; Pottle A; Barbir M; Pennell DJ
J Clin Lipidol; 2019; 13(5):788-796. PubMed ID: 31353231
[TBL] [Abstract][Full Text] [Related]
4. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina.
Khan TZ; Pottle A; Pennell DJ; Barbir MS
Glob Cardiol Sci Pract; 2014; 2014(1):3-12. PubMed ID: 25054114
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease.
Moriarty PM; Gray JV; Gorby LK
J Clin Lipidol; 2019; 13(6):894-900. PubMed ID: 31753721
[TBL] [Abstract][Full Text] [Related]
6. Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.
Julius U; Tselmin S; Schatz U; Fischer S; Birkenfeld AL; Bornstein SR
Atheroscler Suppl; 2019 Dec; 40():1-7. PubMed ID: 31818437
[TBL] [Abstract][Full Text] [Related]
7. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.
Khan TZ; Hsu LY; Arai AE; Rhodes S; Pottle A; Wage R; Banya W; Gatehouse PD; Giri S; Collins P; Pennell DJ; Barbir M
Eur Heart J; 2017 May; 38(20):1561-1569. PubMed ID: 28453721
[TBL] [Abstract][Full Text] [Related]
8. Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a).
Ho JH; Adam S; Liu Y; Azmi S; Dhage S; Syed AA; Ammori BJ; Donn R; Heald A; Gibson MJ; Malik RA; Yang X; Durrington PN; Tsimikas S; Soran H
J Clin Lipidol; 2021; 15(2):320-331. PubMed ID: 33518459
[TBL] [Abstract][Full Text] [Related]
9. Long-term lipoprotein apheresis reduces cardiovascular events in high-risk patients with isolated lipoprotein(a) elevation.
Schumann F; Kassner U; Spira D; Zimmermann FF; Bobbert T; Steinhagen-Thiessen E; Hollstein T
J Clin Lipidol; 2024 Apr; ():. PubMed ID: 38908966
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of raised lipoprotein(a) in patients with refractory angina.
Khan TZ; Rhodes S; Pottle A; Banya W; Smith R; Kabir T; Ilsley C; Pennell DJ; Barbir M
Glob Cardiol Sci Pract; 2015; 2015(2):28. PubMed ID: 26779510
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.
Hohenstein B; Julius U; Lansberg P; Jaeger B; Mellwig KP; Weiss N; Graehlert X; Roeder I; Ramlow W
Atheroscler Suppl; 2017 Nov; 30():180-186. PubMed ID: 29096835
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A;
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552
[TBL] [Abstract][Full Text] [Related]
14. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2.
Lourida ES; Georgiadis AN; Papavasiliou EC; Papathanasiou AI; Drosos AA; Tselepis AD
Arthritis Res Ther; 2007; 9(1):R19. PubMed ID: 17326817
[TBL] [Abstract][Full Text] [Related]
15. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.
Tsimikas S; Bergmark C; Beyer RW; Patel R; Pattison J; Miller E; Juliano J; Witztum JL
J Am Coll Cardiol; 2003 Feb; 41(3):360-70. PubMed ID: 12575961
[TBL] [Abstract][Full Text] [Related]
16. Experience with proprotein convertase subtilisin/kexine type 9 inhibitors (PCSK9i) in patients undergoing lipoprotein apheresis.
Tselmin S; Julius U; Weinert N; Bornstein SR; Schatz U
Atheroscler Suppl; 2019 Dec; 40():38-43. PubMed ID: 31818448
[TBL] [Abstract][Full Text] [Related]
17. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.
Schatz U; Tselmin S; Müller G; Julius U; Hohenstein B; Fischer S; Bornstein SR
Atheroscler Suppl; 2017 Nov; 30():246-252. PubMed ID: 29096845
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
Tselmin S; Müller G; Schatz U; Julius U; Bornstein SR; Hohenstein B
Atheroscler Suppl; 2017 Nov; 30():209-216. PubMed ID: 29096840
[TBL] [Abstract][Full Text] [Related]
19. Anti-Ro and Concomitant Anti-La Autoantibodies Strongly Associated With Anti-oxLDL or Anti-Phospholipid Antibody in Systemic Lupus Erythematosus.
Kurien BT; Fesmire J; Anderson CJ; Scofield RH
J Clin Rheumatol; 2016 Dec; 22(8):418-425. PubMed ID: 27870764
[TBL] [Abstract][Full Text] [Related]
20. Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.
Groß E; Hohenstein B; Julius U
Atheroscler Suppl; 2015 May; 18():226-32. PubMed ID: 25936330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
